Novo Nordisk Seeks New Patients Amid Slowdown in Sales Growth
Novo Nordisk, Europe’s most valuable company, is facing a slowdown in sales growth as its honeymoon phase with Ozempic and Wegovy comes to an end. The pharmaceutical giant beat analyst expectations by growing sales by 25% in 2024, but forecasts a slower growth rate of 16-24% in 2025 due to increased competition and supply constraints. … Read more